Appendix 4D & Half Year Report
Filed with ASX · · 27 pages · English
The loss for the Group after providing for income tax amounted to $696,501 (31 December 2024: $7,444,902) The loss from ordinary activities includes $4,216,373 (31 December 2024: $5,690,862 in Research and Development expenditure). 3. Net tangible assets 4. Dividends There were no dividends paid, recommended or declared during the financial period. 5. Audit review This report is based on the finan
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- Positive 90-day GLP toxicology study results in non-rodents
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Quarterly Activities/Appendix 4C Cash Flow Report
- Binding Commitments Received for a $4 Million Placement
- Trading Halt
Later from Neurotech International
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- NTI secures Notices of Allowance for US patent applications
- US FDA clears IND for NTI164
- Neurotech secures $3.15 million R&D tax incentive loan
- Receipt of Binding Commitments for $4.5m Placement
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International